VLDL hydrolysis by hepatic lipase regulates PPARδ transcriptional responses

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Brown, Jonathan D ^a,b   Oligino, Eric ^a,c   Rader, Daniel J ^d   Saghatelian, Alan ^e   Plutzky, Jorge ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VA Boston Healthcare   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOPHILIN; ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 4; LIVER TRIACYLGLYCEROL LIPASE; MESSENGER RNA; OLEIC ACID; PALMITOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PYRUVATE DEHYDROGENASE KINASE 4; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; FATTY ACID; MEMBRANE PROTEIN; PERILIPIN 2; TRIACYLGLYCEROL LIPASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; GENE CONTROL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METABOLOMICS; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TRANSCRIPTION REGULATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; C57BL MOUSE; CELL LINE; CELL STRAIN COS1; CELL STRAIN HEK293; CERCOPITHECUS; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; HYDROLYSIS; LIVER; METABOLISM; MOUSE MUTANT; MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

MUS;

ANIMALS; BLOTTING, WESTERN; CATALYTIC DOMAIN; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; FATTY ACIDS; HEK293 CELLS; HUMANS; HYDROLYSIS; LIPASE; LIPOPROTEINS, VLDL; LIVER; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, OBESE; MUTATION; PPAR DELTA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION, GENETIC;

EID: 79959982634     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021209     Document Type: Article

References (44)

1. Brown JD, Plutzky J, (2007) Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115: 518-533.
2. Yang X, Lamia KA, Evans RM, (2007) Nuclear receptors, metabolism, and the circadian clock. Cold Spring Harb Symp Quant Biol 72: 387-394.
3. Evans RM, Barish GD, Wang YX, (2004) PPARs and the complex journey to obesity. Nat Med 10: 355-361.
4. Kersten S, Desvergne B, Wahli W, (2000) Roles of PPARs in health and disease. Nature 405: 421-424.
5. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J, (1999) PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125-3131.
6. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, et al. (2000) Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164: 6503-6508.
7. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, et al. (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106: 523-531.
8. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, et al. (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302: 453-457.
9. Forman BM, Chen J, Evans RM, (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94: 4312-4317.
10. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, et al. (2009) Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 138: 476-488.
11. Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, et al. (2003) Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A 100: 2730-2735.
12. Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, et al. (2006) High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res 98: 490-498.
13. Ruby MA, Goldenson B, Orasanu G, Johnston TP, Plutzky J, et al. (2010) VLDL hydrolysis by LPL activates PPAR-alpha through generation of unbound fatty acids. J Lipid Res 51: 2275-2281.
14. Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, et al. (2010) Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators. Circulation 121: 426-435.
15. van Haperen R, Samyn H, van Gent T, Zonneveld AJ, Moerland M, et al. (2009) Novel roles of hepatic lipase and phospholipid transfer protein in VLDL as well as HDL metabolism. Biochim Biophys Acta 1791: 1031-1036.
16. Santamarina-Fojo S, Haudenschild C, Amar M, (1998) The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 9: 211-219.
17. Santamarina-Fojo S, Gonzalez-Navarro H, Freeman L, Wagner E, Nong Z, (2004) Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 24: 1750-1754.
18. Duong M, Psaltis M, Rader DJ, Marchadier D, Barter PJ, et al. (2003) Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids. Biochemistry 42: 13778-13785.
19. Homanics GE, de Silva HV, Osada J, Zhang SH, Wong H, et al. (1995) Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene. J Biol Chem 270: 2974-2980.
20. Braschi S, Couture N, Gambarotta A, Gauthier BR, Coffill CR, et al. (1998) Hepatic lipase affects both HDL and ApoB-containing lipoprotein levels in the mouse. Biochim Biophys Acta 1392: 276-290.
21. Hegele RA, Little JA, Connelly PW, (1991) Compound heterozygosity for mutant hepatic lipase in familial hepatic lipase deficiency. Biochem Biophys Res Commun 179: 78-84.
22. Qian K, Agrawal N, Dichek HL, (2007) Reduced atherosclerosis in chow-fed mice expressing high levels of a catalytically inactive human hepatic lipase. Atherosclerosis 195: 66-74.
23. Nong Z, Gonzalez-Navarro H, Amar M, Freeman L, Knapper C, et al. (2003) Hepatic lipase expression in macrophages contributes to atherosclerosis in apoE-deficient and LCAT-transgenic mice. J Clin Invest 112: 367-378.
24. Lo JC, Wang Y, Tumanov AV, Bamji M, Yao Z, et al. (2007) Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 316: 285-288.
25. Jansen H, Verhoeven AJ, Sijbrands EJ, (2002) Hepatic lipase: a pro- or anti-atherogenic protein? J Lipid Res 43: 1352-1362.
26. Teran-Garcia M, Santoro N, Rankinen T, Bergeron J, Rice T, et al. (2005) Hepatic lipase gene variant -514C>T is associated with lipoprotein and insulin sensitivity response to regular exercise: the HERITAGE Family Study. Diabetes 54: 2251-2255.
27. McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM, et al. (2002) Characterization of the lipolytic activity of endothelial lipase. J Lipid Res 43: 921-929.
28. Chawla A, Lee CH, Barak Y, He W, Rosenfeld J, et al. (2003) PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci U S A 100: 1268-1273.
29. Mineo C, Yuhanna IS, Quon MJ, Shaul PW, (2003) High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 278: 9142-9149.
30. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, et al. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 94: 4318-4323.
31. Tachibana K, Kobayashi Y, Tanaka T, Tagami M, Sugiyama A, et al. (2005) Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. Nucl Recept 3: 3.
32. Kanda T, Brown JD, Orasanu G, Vogel S, Gonzalez FJ, et al. (2009) PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest 119: 110-124.
33. Dugi KA, Amar MJ, Haudenschild CC, Shamburek RD, Bensadoun A, et al. (2000) In vivo evidence for both lipolytic and nonlipolytic function of hepatic lipase in the metabolism of HDL. Arterioscler Thromb Vasc Biol 20: 793-800.
34. Freeman L, Amar MJ, Shamburek R, Paigen B, Brewer HB Jr, et al. (2007) Lipolytic and ligand-binding functions of hepatic lipase protect against atherosclerosis in LDL receptor-deficient mice. J Lipid Res 48: 104-113.
35. Applebaum-Bowden D, Kobayashi J, Kashyap VS, Brown DR, Berard A, et al. (1996) Hepatic lipase gene therapy in hepatic lipase-deficient mice. Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium. J Clin Invest 97: 799-805.
36. Wiesner P, Leidl K, Boettcher A, Schmitz G, Liebisch G, (2009) Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 50: 574-585.
37. Saghatelian A, Trauger SA, Want EJ, Hawkins EG, Siuzdak G, et al. (2004) Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry 43: 14332-14339.
38. Mead JR, Irvine SA, Ramji DP, (2002) Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 80: 753-769.
39. Tagore R, Thomas HR, Homan EA, Munawar A, Saghatelian A, (2008) A global metabolite profiling approach to identify protein-metabolite interactions. J Am Chem Soc 130: 14111-14113.
40. Sanderson LM, Degenhardt T, Koppen A, Kalkhoven E, Desvergne B, et al. (2009) Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver. Mol Cell Biol 29: 6257-6267.
41. Tan NS, Shaw NS, Vinckenbosch N, Liu P, Yasmin R, et al. (2002) Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol 22: 5114-5127.
42. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, et al. (2006) PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 103: 3444-3449.
43. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, et al. (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103: 1489-1498.
44. Chiu HK, Qian K, Ogimoto K, Morton GJ, Wisse BE, et al. (2010) Mice lacking hepatic lipase are lean and protected against diet-induced obesity and hepatic steatosis. Endocrinology 151: 993-1001.